AYTU BioPharma is a pharmaceutical company focused on commercializing therapeutics and consumer health products and developing therapeutics for pediatric-onset or difficult-to-treat diseases. Co. operates through two business segments: the BioPharma segment, consisting of prescription pharmaceutical products; and the Consumer Health segment, which consists of various consumer healthcare products. Co. also has two product candidates in development, AR101 (enzastaurin) for the treatment of vascular Ehlers-Danlos Syndrome and Healight (endotracheal ultraviolet light catheter) for the treatment of severe, difficult-to-treat respiratory infections. The AYTU stock yearly return is shown above.
The yearly return on the AYTU stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AYTU annual return calculation with any dividends reinvested as applicable (on ex-dates).
|